Enlivex (ENLV) vs Gelteq (GELS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Gelteq is the larger company by market cap ($5.6 million vs $5.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ENLV | GELS |
|---|---|---|
| Share price | $0.254 | $0.5212 |
| Market cap | $5.06M | $5.58M |
| 1-day change | -8.30% | -5.03% |
| P/E ratio (TTM) | 0.00 | — |
| EPS (TTM) | $494.00 | $-0.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $27.15 | $2.01 |
| 52-week low | $0.224 | $0.387 |
| Distance from 52-week high | -99.06% | -74.07% |
| Analyst consensus | none | — |
| Avg. price target upside | +31396.06% | — |
| Average volume | 950.55K | 2.91M |
| Shares outstanding | 19.91M | 10.71M |
| Employees | 34 | 7 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Enlivex
ENLV stock →Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as well as develops AllocetraTM intra-articular injection for the treatment of knee osteoarthritis, which is in phase 1/2 trial; intra-articular AllocetraTM in osteoarthritis of the temporomandibular joint (TMJ); and Allocetra-OTS for the treatment of organ failure in adult sepsis patients, which is in phase 2.
Health Care · Biotechnology: Pharmaceutical Preparations · 34 employees
About Gelteq
GELS stock →Gelteq Limited focuses on developing and commercializing white label gel-based delivery solutions for humans and animals in the United States of America, China and Australia. It offers edible gels for prescription drugs, nutraceuticals, pet care, and other products, as well as for sports and over-the-counter products.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
ENLV vs GELS FAQ
Which is bigger, Enlivex or Gelteq?
Gelteq (GELS) is larger, with a market capitalization of $5.58M compared with $5.06M for Enlivex (ENLV).
Are Enlivex and Gelteq in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.